BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31517821)

  • 1. An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer.
    Dolan RD; Laird BJA; Klepstad P; Kaasa S; Horgan PG; Paulsen Ø; McMillan DC
    Medicine (Baltimore); 2019 Sep; 98(37):e17019. PubMed ID: 31517821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
    Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
    Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: Implications for a clinically important framework in the assessment and treatment of advanced cancer.
    Dolan RD; Daly L; Sim WMJ; Fallon M; Ryan A; McMillan DC; Laird BJ
    Clin Nutr; 2020 Sep; 39(9):2889-2895. PubMed ID: 31926762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer.
    Rocha BMM; Dolan RD; Paiva CE; McGovern J; Paiva BSR; Preto DD; McMillan DC; Maia YCP; Laird BJ
    J Pain Symptom Manage; 2023 Apr; 65(4):348-357. PubMed ID: 36493981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
    Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
    Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia.
    Ruan GT; Xie HL; Yuan KT; Lin SQ; Zhang HY; Liu CA; Shi JY; Ge YZ; Song MM; Hu CL; Zhang XW; Liu XY; Yang M; Wang KH; Zheng X; Chen Y; Hu W; Cong MH; Zhu LC; Deng L; Shi HP
    J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2813-2823. PubMed ID: 37902006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Relationship between ECOG-PS, mGPS, BMI/WL Grade and Body Composition and Physical Function in Patients with Advanced Cancer.
    Dolan RD; Daly LE; Simmons CP; Ryan AM; Sim WM; Fallon M; Power DG; Wilcock A; Maddocks M; Bennett MI; Usborne C; Laird BJ; McMillan DC
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
    Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
    Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.
    Simmons CP; Koinis F; Fallon MT; Fearon KC; Bowden J; Solheim TS; Gronberg BH; McMillan DC; Gioulbasanis I; Laird BJ
    Lung Cancer; 2015 Jun; 88(3):304-9. PubMed ID: 25870155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory Response.
    Laird BJ; Fallon M; Hjermstad MJ; Tuck S; Kaasa S; Klepstad P; McMillan DC
    J Clin Oncol; 2016 Aug; 34(23):2769-75. PubMed ID: 27354484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
    Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment.
    Alan O; Telli TA; Basoğlu T; Arikan R; Demircan NC; Ercelep O; Bozkurt S; Atasoy BM; Dane F; Yumuk PF
    Clin Neurol Neurosurg; 2020 Sep; 196():105976. PubMed ID: 32531614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system.
    Laird BJ; Kaasa S; McMillan DC; Fallon MT; Hjermstad MJ; Fayers P; Klepstad P
    Clin Cancer Res; 2013 Oct; 19(19):5456-64. PubMed ID: 23938289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
    Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
    Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care.
    Pantano Nde P; Paiva BS; Hui D; Paiva CE
    J Pain Symptom Manage; 2016 Feb; 51(2):270-7. PubMed ID: 26598040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer.
    Ruan GT; Xie HL; Zhang HY; Zhang Q; Deng L; Wang ZW; Zhang X; Ge YZ; Hu CL; Tang M; Song MM; Zhang XW; Liu T; Li XR; Zhang KP; Yang M; Gong YZ; Chen YB; Yu KY; Cong MH; Pan L; Tang WZ; Wang KH; Shi HP
    Clin Nutr; 2022 Oct; 41(10):2284-2294. PubMed ID: 36096062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of quality of life in patients with incurable cancer.
    Daly LE; Dolan RD; Power DG; Ní Bhuachalla É; Sim W; Cushen SJ; Fallon M; Simmons C; McMillan DC; Laird BJ; Ryan AM
    Cancer; 2020 Jun; 126(12):2872-2882. PubMed ID: 32267548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.
    Proctor MJ; Morrison DS; Talwar D; Balmer SM; O'Reilly DS; Foulis AK; Horgan PG; McMillan DC
    Br J Cancer; 2011 Feb; 104(4):726-34. PubMed ID: 21266974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study.
    Takahashi M; Takahashi M; Komine K; Yamada H; Kasahara Y; Chikamatsu S; Okita A; Ito S; Ouchi K; Okada Y; Imai H; Saijo K; Shirota H; Takahashi S; Mori T; Shimodaira H; Ishioka C
    PLoS One; 2017; 12(6):e0179694. PubMed ID: 28640844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.